11
6

Access to Prescription Digital Therapeutics Act of 2025

6/6/2025, 6:11 PM

Summary of Bill HR 3288

H.R. 3288 of the 119th Congress, introduced on May 8, 2025, aims to amend titles XVIII and XIX of the Social Security Act to include prescription digital therapeutics in the coverage provided by the Medicare and Medicaid programs.

Congressional Summary of HR 3288

Access to Prescription Digital Therapeutics Act of 2025

This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.

Current Status of Bill HR 3288

Bill HR 3288 is currently in the status of Bill Introduced since May 8, 2025. Bill HR 3288 was introduced during Congress 119 and was introduced to the House on May 8, 2025.  Bill HR 3288's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of May 8, 2025

Bipartisan Support of Bill HR 3288

Total Number of Sponsors
7
Democrat Sponsors
0
Republican Sponsors
7
Unaffiliated Sponsors
0
Total Number of Cosponsors
3
Democrat Cosponsors
3
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 3288

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 3288

To amend titles XVIII and XIX of the Social Security Act to provide for coverage of prescription digital therapeutics under the Medicare and Medicaid programs, and for other purposes.
To amend titles XVIII and XIX of the Social Security Act to provide for coverage of prescription digital therapeutics under the Medicare and Medicaid programs, and for other purposes.

Comments